Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 jobs. According to the company, its cash reserves will last until the end of 2027. But behind the strategic overhaul lies an increasingly strained financial position. Its broad pipeline is likely to require much stricter prioritization.
ADVERTISEMENT
Tag Archive for: commercial strategy
The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.



